National Institute for Health and Clinical Excellence (NICE)
NICE recommends 3 treatments for COVID-19 in draft guidance
Three treatments for COVID have been recommended in draft NICE guidance released today for public consultation.
The recommended treatments are:
- Nirmatrelvir plus ritonavir (also called Paxlovid and made by Pfizer).
- Tocilizumab (also called RoActemra and made by Roche).
- Baricitinib (also called Olumiant and made by Eli Lilly and company, subject to it receiving a marketing authorisation in Great Britain for treating COVID-19).
Several other medicines are not recommended at this stage. However NICE stands ready to work with companies and NHS England to look for solutions during the public consultation.
Helen Knight, interim director of medicines evaluation at NICE, said: “Our task has been to evaluate the clinical and cost-effectiveness of treatments for COVID-19, many of which are currently being made available in England under interim UK-wide pandemic-specific access arrangements. In doing so we need to strike a balance between the effectiveness of a treatment and the best use of public funding as we come out of the pandemic, to ensure the NHS can continue to deliver maximum value to the taxpayer.
“The evidence for all the treatments we’ve looked at is highly uncertain because most of the studies were carried out before the emergence of the now dominant Omicron variant of COVID-19.”
NICE has been asked to review the clinical and cost-effectiveness of medicines currently being used in the NHS to treat COVID-19. The appraisal is about routine commissioning of these medicines and does not address their use in exceptional (i.e. pandemic) circumstances.
Although much of the clinical evidence available to the independent committee was based on studies done before the emergence of the Omicron variant, and is therefore uncertain, nirmatrelvir plus ritonavir, tocilizumab and baricitinib are recommended because there is some evidence suggesting they are effective in treating COVID-19. These treatments were found to be cost effective.
The evaluation also looks at the following treatments in the draft guidance:
- Casirivimab plus imdevimab and sotrovimab are not recommended as the independent committee reviewing the evidence felt it was highly uncertain whether these treatments were effective against the Omicron variant. The committee also noted the WHO’s and FDA’s recommendations against using casirivimab plus imdevimab and sotrovimab for the Omicron variant.
- Tixagevimab plus cilgavimab is also not recommended as the committee felt it was highly uncertain whether it was effective against the Omicron variant.
- Molnupiravir and remdesivir are not recommended. While there is some clinical evidence that they are effective at treating COVID-19 they were not found to be cost effective.
Helen Knight added: “We are ready to work with all the companies whose products have not been recommended in this draft guidance, and with NHS England, to explore whether there is scope for any commercial or other solutions that could address the issues highlighted by the independent appraisal committee.
“In addition, the hospitalisation rate was found to be a key driver of cost-effectiveness and this rate has changed over time. The committee would welcome additional evidence on the most appropriate hospitalisation rate for the high-risk group to inform its decision-making. In the meantime, we would encourage anyone with an interest in this topic to send us their comments on these draft recommendations.”
This evaluation looks at treatments for COVID-19. There is a separate evaluation for tixagevimab plus cilgavimab as a prophylaxis. This means for use as a preventative medicine to protect people from developing COVID-19. NICE currently expects to publish final guidance for the appraisal of tixagevimab plus cilgavimab for prophylaxis in spring 2023.
The recommendations relating to the use of medicines for COVID-19 in the NICE rapid guideline on managing COVID-19, developed during the pandemic will be updated when NICE’s final recommendations on therapeutics for COVID-19 are published.
The recommendations published today are draft and could change following public consultation. Until NICE publishes its final guidance, access to COVID medicines will continue to be guided by the published UK-wide clinical access policies agreed by the UK Chief Medical Officers. Once published, the final guidance will inform routine commissioning decisions for these treatments.
Latest News from
National Institute for Health and Clinical Excellence (NICE)
New life-extending treatment for rare forms of advanced gastroesophageal cancer recommended by NICE24/11/2022 11:15:00
Around 3,000 people could be eligible for a new life-extending combination therapy to treat rare forms of gastroesophageal cancer after NICE published final draft guidance today (24 November 2022)
NICE leads the way to develop a new approach to routinely value and pay for crucial antimicrobials22/11/2022 09:15:00
Blog posted by: James Love-Koh, Scientific Adviser – Science Policy & Research Programme, NICE, 21 November 2022.
Fetal balloon procedure is safe for delivering ‘stuck’ babies, NICE says17/11/2022 13:10:00
A balloon inflated underneath a baby’s head after they have become stuck in the pelvis during labour could be used to safely deliver them, NICE has said
Targeted treatment for rare form of aggressive lung cancer gets NICE approval17/11/2022 12:10:00
Mobocertinib recommended as a treatment for a rare and aggressive form of lung cancer
NICE recommends adapted shoes for people with severe osteoarthritis16/11/2022 11:15:00
People with osteoarthritis who are eligible for knee surgery could be offered specially adapted shoes to help with their painful and stiff knees following a draft recommendation by NICE.
NICE final draft guidance adds further treatment option for triple-negative breast cancer10/11/2022 09:05:00
NICE has recently published final draft guidance which recommends pembrolizumab as an option for people with a type of breast cancer called triple-negative breast cancer.
NICE conditionally recommends digital cognitive behaviour therapies for use in the NHS to help children and young people with symptoms of mild to moderate anxiety04/11/2022 14:15:00
Draft guidance released for consultation today (Friday 4th Nov) states the technologies can be used with support from a mental health professional, while further evidence is generated to check if the benefits they offer are realised in practice.
Towards a new partnership – NICE and the Voluntary and Community Sector04/11/2022 12:33:00
Blog posted by: Victoria Thomas, Head of Public Involvement at NICE, 03 November 2022.
NICE partners with international health technology assessment bodies to boost collaboration on shared opportunities and challenges13/10/2022 11:15:00
SIX health technology assessment (HTA) bodies from three continents are to collaborate on a range of topics that will benefit people accessing healthcare around the world.